For research use only. Not for therapeutic Use.
JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1[1].
JC2-11 (250 μg/mouse; i.p.; single dose) significantly inhibits the release of caspase-1 (p20) and IL-1β in non-canonical (NC) inflammatory bodies, and weakens the activation of NC inflammatory bodies of C57BL/6 mice model[1].
| Catalog Number | I041953 |
| CAS Number | 937820-89-8 |
| Synonyms | (E)-1-(3-fluoro-4-methoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one |
| Molecular Formula | C17H15FO4 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H15FO4/c1-21-16-8-5-12(10-13(16)18)14(19)6-3-11-4-7-15(20)17(9-11)22-2/h3-10,20H,1-2H3/b6-3+ |
| InChIKey | YYAIFDXWRNNHAW-ZZXKWVIFSA-N |
| SMILES | COC1=C(C=C(C=C1)C(=O)C=CC2=CC(=C(C=C2)O)OC)F |
| Reference | [1]. Lee G, et al, JC2-11, a benzylideneacetophenone derivative, attenuates inflammasome activation. Sci Rep. 2022 Dec 28;12(1):22484. |
